Literature DB >> 26169830

Expression of the CTCFL Gene during Mouse Embryogenesis Causes Growth Retardation, Postnatal Lethality, and Dysregulation of the Transforming Growth Factor β Pathway.

Leyla Sati1, Caroline Zeiss2, Krishna Yekkala2, Ramazan Demir1, James McGrath3.   

Abstract

CTCFL, a paralog of CTCF, also known as BORIS (brother of regulator of imprinted sites), is a testis-expressed gene whose function is largely unknown. Its product is a cancer testis antigen (CTA), and it is often expressed in tumor cells and also seen in two benign human vascular malformations, juvenile angiofibromas and infantile hemangiomas. To understand the function of Ctcfl, we created tetracycline-inducible Ctcfl transgenic mice. We show that Ctcfl expression during embryogenesis results in growth retardation, eye malformations, multiorgan pathologies, vascular defects, and neonatal death. This phenotype resembles prior mouse models that perturb the transforming growth factor β (TGFB) pathway. Embryonic stem (ES) cells with the Ctcfl transgene reproduce the phenotype in ES cell-tetraploid chimeras. Transcriptome sequencing of the Ctcfl ES cells revealed 14 genes deregulated by Ctcfl expression. Bioinformatic analysis revealed the TGFB pathway as most affected by embryonic Ctcfl expression. Understanding the consequence of Ctcfl expression in nontesticular cells and elucidating downstream targets of Ctcfl could explain the role of its product as a CTA and its involvement in two, if not more, human vascular malformations.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26169830      PMCID: PMC4561735          DOI: 10.1128/MCB.00381-15

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  68 in total

1.  Molecular architecture of CTCFL.

Authors:  Amy E Campbell; Selena R Martinez; J J L Miranda
Journal:  Biochem Biophys Res Commun       Date:  2010-05-08       Impact factor: 3.575

2.  Rec8-containing cohesin maintains bivalents without turnover during the growing phase of mouse oocytes.

Authors:  Kikuë Tachibana-Konwalski; Jonathan Godwin; Louise van der Weyden; Lysie Champion; Nobuaki R Kudo; David J Adams; Kim Nasmyth
Journal:  Genes Dev       Date:  2010-10-22       Impact factor: 11.361

3.  A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection.

Authors:  Zhong Deng; Zhuo Wang; Nick Stong; Robert Plasschaert; Aliah Moczan; Horng-Shen Chen; Sufeng Hu; Priyankara Wikramasinghe; Ramana V Davuluri; Marisa S Bartolomei; Harold Riethman; Paul M Lieberman
Journal:  EMBO J       Date:  2012-09-25       Impact factor: 11.598

Review 4.  BORIS in human cancers -- a review.

Authors:  Irena Martin-Kleiner
Journal:  Eur J Cancer       Date:  2011-10-21       Impact factor: 9.162

5.  Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas.

Authors:  E P Böttinger; J L Jakubczak; I S Roberts; M Mumy; P Hemmati; K Bagnall; G Merlino; L M Wakefield
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

6.  Functional annotation of a full-length mouse cDNA collection.

Authors:  J Kawai; A Shinagawa; K Shibata; M Yoshino; M Itoh; Y Ishii; T Arakawa; A Hara; Y Fukunishi; H Konno; J Adachi; S Fukuda; K Aizawa; M Izawa; K Nishi; H Kiyosawa; S Kondo; I Yamanaka; T Saito; Y Okazaki; T Gojobori; H Bono; T Kasukawa; R Saito; K Kadota; H Matsuda; M Ashburner; S Batalov; T Casavant; W Fleischmann; T Gaasterland; C Gissi; B King; H Kochiwa; P Kuehl; S Lewis; Y Matsuo; I Nikaido; G Pesole; J Quackenbush; L M Schriml; F Staubli; R Suzuki; M Tomita; L Wagner; T Washio; K Sakai; T Okido; M Furuno; H Aono; R Baldarelli; G Barsh; J Blake; D Boffelli; N Bojunga; P Carninci; M F de Bonaldo; M J Brownstein; C Bult; C Fletcher; M Fujita; M Gariboldi; S Gustincich; D Hill; M Hofmann; D A Hume; M Kamiya; N H Lee; P Lyons; L Marchionni; J Mashima; J Mazzarelli; P Mombaerts; P Nordone; B Ring; M Ringwald; I Rodriguez; N Sakamoto; H Sasaki; K Sato; C Schönbach; T Seya; Y Shibata; K F Storch; H Suzuki; K Toyo-oka; K H Wang; C Weitz; C Whittaker; L Wilming; A Wynshaw-Boris; K Yoshida; Y Hasegawa; H Kawaji; S Kohtsuki; Y Hayashizaki
Journal:  Nature       Date:  2001-02-08       Impact factor: 49.962

7.  Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.

Authors:  Koji Okabayashi; Tomonobu Fujita; Junichiro Miyazaki; Tsutomu Okada; Takashi Iwata; Nobumaru Hirao; Shinobu Noji; Nobuo Tsukamoto; Naoki Goshima; Hirotoshi Hasegawa; Hiroya Takeuchi; Masakazu Ueda; Yuko Kitagawa; Yutaka Kawakami
Journal:  Cancer Sci       Date:  2012-07-16       Impact factor: 6.716

8.  Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.

Authors:  A Nagy; J Rossant; R Nagy; W Abramow-Newerly; J C Roder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  Functional analysis of activins during mammalian development.

Authors:  M M Matzuk; T R Kumar; A Vassalli; J R Bickenbach; D R Roop; R Jaenisch; A Bradley
Journal:  Nature       Date:  1995-03-23       Impact factor: 49.962

10.  Loss of maternal CTCF is associated with peri-implantation lethality of Ctcf null embryos.

Authors:  James M Moore; Natalia A Rabaia; Leslie E Smith; Sara Fagerlie; Kay Gurley; Dmitry Loukinov; Christine M Disteche; Steven J Collins; Christopher J Kemp; Victor V Lobanenkov; Galina N Filippova
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

View more
  5 in total

1.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

2.  Cancer/testis antigens as molecular drug targets using network pharmacology.

Authors:  Anuj Kumar; Drista Sharma; M L Aggarwal; K M Chacko; Tarun Kumar Bhatt
Journal:  Tumour Biol       Date:  2016-10-05

3.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

4.  Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation.

Authors:  Mayilaadumveettil Nishana; Caryn Ha; Javier Rodriguez-Hernaez; Ali Ranjbaran; Erica Chio; Elphege P Nora; Sana B Badri; Andreas Kloetgen; Benoit G Bruneau; Aristotelis Tsirigos; Jane A Skok
Journal:  Genome Biol       Date:  2020-05-11       Impact factor: 13.583

5.  BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF.

Authors:  H H Pulkkinen; M Kiema; S Ylä-Herttuala; Johanna P Laakkonen; J P Lappalainen; A Toropainen; M Beter; A Tirronen; L Holappa; H Niskanen; M U Kaikkonen
Journal:  Angiogenesis       Date:  2020-10-06       Impact factor: 10.658

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.